ANNX vs. TBPH, PLRX, ENTA, AKRO, SNDX, BHC, VERA, DCPH, MRVI, and RCKT
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Theravance Biopharma (TBPH), Pliant Therapeutics (PLRX), Enanta Pharmaceuticals (ENTA), Akero Therapeutics (AKRO), Syndax Pharmaceuticals (SNDX), Bausch Health Companies (BHC), Vera Therapeutics (VERA), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
Annexon currently has a consensus price target of $15.33, indicating a potential upside of 167.13%. Theravance Biopharma has a consensus price target of $20.50, indicating a potential upside of 133.75%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Theravance Biopharma.
Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
In the previous week, Annexon had 17 more articles in the media than Theravance Biopharma. MarketBeat recorded 19 mentions for Annexon and 2 mentions for Theravance Biopharma. Annexon's average media sentiment score of 0.55 beat Theravance Biopharma's score of -0.67 indicating that Annexon is being referred to more favorably in the media.
Annexon has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
99.1% of Theravance Biopharma shares are held by institutional investors. 12.7% of Annexon shares are held by insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Theravance Biopharma received 291 more outperform votes than Annexon when rated by MarketBeat users. However, 74.60% of users gave Annexon an outperform vote while only 63.53% of users gave Theravance Biopharma an outperform vote.
Annexon has a net margin of 0.00% compared to Theravance Biopharma's net margin of -72.79%. Theravance Biopharma's return on equity of -18.97% beat Annexon's return on equity.
Summary
Annexon beats Theravance Biopharma on 9 of the 16 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
